Related references
Note: Only part of the references are listed.Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Tom W. J. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Denis Poddubnyy et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis
Yoshihito Shima et al.
Modern Rheumatology (2014)
Association between cytokines and methylation of SOCS-1 in serum of patients with ankylosing spondylitis
Ning-Sheng Lai et al.
MOLECULAR BIOLOGY REPORTS (2014)
Histomorphologic and Histomorphometric Characteristics of Zygapophyseal Joint Remodeling in Ankylosing Spondylitis
Janine Bleil et al.
ARTHRITIS & RHEUMATOLOGY (2014)
In Situ Analysis of Interleukin-23-and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis
Heiner Appel et al.
ARTHRITIS AND RHEUMATISM (2013)
Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers
Ugo Fiocco et al.
JOINT BONE SPINE (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
Interleukin 6 Blockade in Spondyloarthritis
Eugenie Koumakis et al.
JOURNAL OF RHEUMATOLOGY (2012)
ASDAS, BASDAI and different treatment responses and their relation to biomarkers of infl ammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors
Susanne Juhl Pedersen et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Ankylosing Spondylitis Refractory to Tumor Necrosis Factor Blockade Responds to Tocilizumab
Jean-David Cohen et al.
JOURNAL OF RHEUMATOLOGY (2011)
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
Heiner Appel et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Mixed response to tocilizumab for ankylosing spondylitis
Joerg C. Henes et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Pathogenesis of ankylosing spondylitis
Lai-Shan Tam et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis
Martin Rudwaleit et al.
JOURNAL OF RHEUMATOLOGY (2009)
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
S. Visvanathan et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis
A. Bal et al.
CLINICAL RHEUMATOLOGY (2007)
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis
Heiner Appel et al.
ARTHRITIS AND RHEUMATISM (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis:: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases
R. J. Francois et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
M Mihara et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year?
A Falkenbach et al.
RHEUMATOLOGY INTERNATIONAL (2000)
Share Paper
